Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies
December 01, 2015 07:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and...
Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
November 24, 2015 11:15 ET
|
Adaptimmune Therapeutics plc
OXFORD, United Kingdom and PHILADELPHIA, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today...
Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16
November 13, 2015 07:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today reported...
Adaptimmune to Participate in the Jefferies Autumn 2015 Global Healthcare Conference
November 12, 2015 10:16 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today announced that...
Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
November 05, 2015 08:15 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, UK, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today presents...
Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
October 30, 2015 09:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell...
Adaptimmune to Participate in the 2015 BIO Investor Forum
October 16, 2015 10:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company...
Adaptimmune Reports Full Fiscal Year 2015 Financial Results
October 13, 2015 06:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company...
Adaptimmune Growth Leads to Long-Term Expansion Plans in Philadelphia
October 09, 2015 08:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, UK, Oct. 09, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc. (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on...
Adaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015
October 07, 2015 09:13 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, UK, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused...